<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34397416</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-8908</ISSN><JournalIssue CitedMedium="Internet"><Volume>83</Volume><Issue>3</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>A Novel Genetic Marker for the C9orf72 Repeat Expansion in the Finnish Population.</ArticleTitle><Pagination><StartPage>1325</StartPage><EndPage>1332</EndPage><MedlinePgn>1325-1332</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JAD-210599</ELocationID><Abstract><AbstractText Label="BACKGROUND">C9orf72 repeat expansion (C9exp) is the most common genetic cause underlying frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). However, detection of the C9exp requires elaborative methods.</AbstractText><AbstractText Label="OBJECTIVE">Identification of C9exp carriers from genotyped cohorts could be facilitated by using single nucleotide polymorphisms (SNPs) as markers for the C9exp.</AbstractText><AbstractText Label="METHODS">We elucidated the potential of the previously described Finnish risk haplotype, defined by the SNP rs3849942, to identify potential C9exp carriers among 218,792 Finns using the FinnGen database. The haplotype approach was first tested in an idiopathic normal pressure hydrocephalus (iNPH) patient cohort (European Alzheimer's Disease DNA BioBank) containing C9exp carriers by comparing intermediate (15-30) and full-length (&gt;&#x200a;60 repeats) C9exp carriers (n&#x200a;=&#x200a;41) to C9exp negative patients (&lt;&#x200a;15 repeats, n&#x200a;=&#x200a;801).</AbstractText><AbstractText Label="RESULTS">In this analysis, rs3849942 was associated with carriership of C9exp (OR 8.44, p&#x200a;&lt;&#x200a;2&#xd7;10-15), while the strongest association was found with rs139185008 (OR 39.4, p&#x200a;&lt;&#x200a;5&#xd7;10-18). Unbiased analysis of rs139185008 in FinnGen showed the strongest association with FTLD (OR 4.38, 3&#xd7;10-15) and motor neuron disease ALS (OR 5.19, 3&#xd7;10-21). rs139185008 was the top SNP in all diseases (iNPH, FTLD, ALS), and further showed a strong association with ALS in the UK Biobank (p&#x200a;=&#x200a;9.0&#xd7;10-8).</AbstractText><AbstractText Label="CONCLUSION">Our findings suggest that rs139185008 is a useful marker to identify potential C9exp carriers in the genotyped cohorts and biobanks originating from Finland.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rostalski</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korhonen</LastName><ForeName>Ville</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Neurocenter, Neurosurgery, Kuopio University Hospital and University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuulasmaa</LastName><ForeName>Teemu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solje</LastName><ForeName>Eino</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine - Neurology, University of Eastern Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuro Center, Neurology, Kuopio University Hospital, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kr&#xfc;ger</LastName><ForeName>Johanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Research Unit of Clinical Neuroscience, Neurology, University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Research Center (MRC), Oulu University Hospital, Oulu, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gen</LastName><ForeName>Finn</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, Helsinki University Hospital and Translational Immunology Program, Biomedicum, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaivola</LastName><ForeName>Karri</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Helsinki University Hospital and Translational Immunology Program, Biomedicum, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eide</LastName><ForeName>Per Kristian</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Oslo University Hospital-Rikshospitalet; and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Jean-Charles</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE facteurs de risque et d&#xe9;terminants mol&#xe9;culaires des maladies li&#xe9;s au vieillissement, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Julkunen</LastName><ForeName>Valtteri</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine - Neurology, University of Eastern Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuro Center, Neurology, Kuopio University Hospital, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tienari</LastName><ForeName>Pentti J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Helsinki University Hospital and Translational Immunology Program, Biomedicum, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Remes</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Research Unit of Clinical Neuroscience, Neurology, University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Research Center (MRC), Oulu University Hospital, Oulu, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leinonen</LastName><ForeName>Ville</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Neurocenter, Neurosurgery, Kuopio University Hospital and University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hiltunen</LastName><ForeName>Mikko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haapasalo</LastName><ForeName>Annakaisa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005387" MajorTopicYN="N" Type="Geographic">Finland</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005819" MajorTopicYN="Y">Genetic Markers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">C9orf72</Keyword><Keyword MajorTopicYN="N">DNA repeat expansion</Keyword><Keyword MajorTopicYN="N">frontotemporal lobar degeneration</Keyword><Keyword MajorTopicYN="N">motor neuron disease</Keyword><Keyword MajorTopicYN="N">polymorphism</Keyword><Keyword MajorTopicYN="N">single nucleotide</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>16</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34397416</ArticleId><ArticleId IdType="doi">10.3233/JAD-210599</ArticleId><ArticleId IdType="pii">JAD210599</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>